Veno-occlusive Disease
9
1
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
44%
4 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Defibrotide Dose-escalation for SOS Post-HSCT
Ultrasound Elastography to Predict Development of SOS
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
5-day Defibrotide Treatment for Hepatic SOS/VOD
Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer